Physicians

Department / Division
Pediatrics / Pediatrics-Hematology/Oncology

Address
DUMC 102382
Durham, NC 27710

Appointment Telephone
919-684-3401

Office Telephone
919-684-3401

Fax Telephone
919-681-7950

Training

• MD, Mount Sinai School of Medicine of New York University, 1985

Residency

• Pediatrics, Children's Hospital at Harvard (Massachusetts), 1985-1988

Fellowship

• Pediatric Hematology/Oncology, Children's Hospital, Dana Farber Cancer Center (Massachusetts)

Clinical Interests
Pediatric oncology, new therapeutics for neuroblastoma, apheresis, high-dose chemotherapy, clinical trials in childhood cancer

Research Interests
The emphasis of Dr Kreissman's clinical research involves the study of childhood neuroblastoma.  Neuroblastoma is the most common extracranial solid tumor of childhood and this disease has a diverse clinical phenotype and prognosis.  Dr Kreissman has developed, written, and served as national protocol chairman for 2 clinical trials designed to improve outcome for children with the high risk form of this disease through the Children's Oncology Group (COG). The most recent protocol is " A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma" completed accrual and results are being analyzed. Dr. Kreissman also serves as a member of the Neuroblastoma committees for COG, the COG Voting Body Steering Committee, and is PI for COG studies at Duke as well as the Duke PI for the New Approaches to Neuroblastoma Therapy (NANT) consortium. She is involved in designing and implimenting additional new protocols for the treatment of neuroblastoma.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• EMD Pharmaceuticals (Merck KGaA, Germany - not Merck USA)

Representative Publications
Bensimhon P, Villablanca JG, Sender LS, Matthay KK, Park JR, Seeger R, London WB, Yap JS, Kreissman SG. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. Pediatr Blood Cancer. 2010 Apr;54(4):596-602. (2010) Abstract

Cairo MS, Davenport V, Bessmertny O, Goldman SC, Berg SL, Kreissman SG, Laver J, Shen V, Secola R, van de Ven C, Reaman GH. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br J Haematol. 2005 Jan;128(1):49-58. (2005) Abstract

Kreissman S, Haase G. "Adjuvant Therapy for Childhood Cancer" in Pediatric Surgery Ed: Ashcraft (3rd edition)W.B. Saunders Philadelphia. 2000; 63: 830-858. (Book chapter) (2000)

Kreissman SG, Rackoff W, Lee M, Breitfeld PP. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. J Pediatr Hematol Oncol. 1997 Jul-Aug;19(4):309-12. (1997) Abstract

Kreissman SG. Molecular genetics: toward an understanding of childhood cancer. Semin Pediatr Surg. 1993 Feb;2(1):2-10. (1993) Abstract

West DC, Shamberger RC, Macklis RM, Kozakewich HP, Wayne AS, Kreissman SG, Korf BR, Lavally B, Grier HE. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. J Clin Oncol. 1993 Jan;11(1):84-90. (1993) Abstract

Kreissman SG, Gelber RD, Cohen HJ, Clavell LA, Leavitt P, Sallan SE. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer. 1992 Oct 15;70(8):2208-13. (1992) Abstract